TCV Trust & Wealth Management Inc. Has $6.85 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

TCV Trust & Wealth Management Inc. trimmed its position in Merck & Co., Inc. (NYSE:MRK) by 0.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 60,329 shares of the company’s stock after selling 559 shares during the quarter. TCV Trust & Wealth Management Inc.’s holdings in Merck & Co., Inc. were worth $6,851,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MRK. Industrial Alliance Investment Management Inc. raised its stake in shares of Merck & Co., Inc. by 2.6% during the first quarter. Industrial Alliance Investment Management Inc. now owns 3,193 shares of the company’s stock worth $421,000 after buying an additional 80 shares during the last quarter. IRON Financial LLC grew its holdings in Merck & Co., Inc. by 4.6% during the 2nd quarter. IRON Financial LLC now owns 1,811 shares of the company’s stock worth $224,000 after acquiring an additional 80 shares during the period. Argent Capital Management LLC raised its position in shares of Merck & Co., Inc. by 0.8% during the 2nd quarter. Argent Capital Management LLC now owns 10,521 shares of the company’s stock valued at $1,302,000 after acquiring an additional 81 shares during the last quarter. Forza Wealth Management LLC lifted its stake in shares of Merck & Co., Inc. by 0.8% in the 2nd quarter. Forza Wealth Management LLC now owns 10,480 shares of the company’s stock valued at $1,297,000 after purchasing an additional 82 shares during the period. Finally, Vista Investment Partners LLC boosted its position in shares of Merck & Co., Inc. by 2.0% in the 2nd quarter. Vista Investment Partners LLC now owns 4,164 shares of the company’s stock worth $516,000 after purchasing an additional 82 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $103.98 on Friday. The stock has a market capitalization of $263.36 billion, a price-to-earnings ratio of 19.29, a PEG ratio of 1.52 and a beta of 0.39. Merck & Co., Inc. has a 12 month low of $99.80 and a 12 month high of $134.63. The firm has a fifty day simple moving average of $113.52 and a 200 day simple moving average of $121.63. The company has a current ratio of 1.47, a quick ratio of 1.22 and a debt-to-equity ratio of 0.80.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, July 30th. The company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.12. Merck & Co., Inc. had a return on equity of 40.69% and a net margin of 21.99%. The business had revenue of $16.10 billion during the quarter, compared to analysts’ expectations of $15.87 billion. During the same period last year, the firm posted ($2.06) EPS. The firm’s revenue for the quarter was up 7.1% compared to the same quarter last year. Research analysts forecast that Merck & Co., Inc. will post 7.8 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on MRK shares. Morgan Stanley upped their price objective on Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a report on Thursday, July 11th. Citigroup cut their price target on shares of Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Friday. Truist Financial reduced their price objective on shares of Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Sanford C. Bernstein began coverage on shares of Merck & Co., Inc. in a research note on Thursday, October 17th. They issued a “market perform” rating and a $115.00 target price for the company. Finally, Wells Fargo & Company reduced their price target on shares of Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $131.50.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.